文献速递乳房整形与再造美容整形

包膜切除术类型对乳房假体取出后全身症状改善的影响:ASERF 女性全身症状-生物样本分析研究第一部分

Impact of Capsulectomy Type on Post-Explantation Systemic Symptom Improvement: Findings From the ASERF Systemic Symptoms in Women-Biospecimen Analysis Study: Part 1.
PubMed 文献 · Aesthet Surg J · 2022-01-01

这项前瞻性盲法研究纳入150例受试者,分为有症状要求取出假体组、无症状要求取出或更换假体组及从未植入医疗器械的乳房提升术组,比较不同包膜切除术类型对自我报告乳房假体疾病患者术后全身症状改善的影响。结果显示,完整全包膜切除、全包膜切除或部分包膜切除在症状改善上相似,基于包膜切除术类型的症状减少无统计学差异;自我报告乳房假体疾病的患者取出假体后症状有统计学显著改善,且这种改善至少持续6个月。

要点

  • 自我报告乳房假体疾病的患者取出假体后症状有统计学显著改善,且至少持续6个月。
  • 完整全包膜切除、全包膜切除或部分包膜切除的症状改善相似,基于包膜切除术类型的症状减少无统计学差异。
  • 该研究为前瞻性盲法研究,2019-2021年纳入150例受试者,均分为3组。

核心结论

  • 自我报告乳房假体疾病的患者取出假体后症状有统计学显著改善,且这种改善至少持续6个月。
  • 无论采用何种包膜切除术类型,自我报告的全身症状改善均可见。

研究设计与样本

  • 前瞻性盲法研究,2019-2021年纳入150例连续受试者,均分为3组:A组为有归因于假体的全身症状并要求取出假体的女性;B组为要求取出或更换假体但无归因于假体症状的女性;C组为从未植入任何医疗器械的乳房提升术女性。
  • 术前及术后3-6周、6个月和1年获取基线人口学数据和全身症状调查(包括PROMIS验证问卷)。
  • 采集所有3组的血液,并采集A组和B组的假体包膜。
  • 研究由Aesthetic Surgery Education and Research Foundation(ASERF)资助。

主要发现

  • 3-6周随访率所有3组为98%-100%,6个月为78%-98%,1年数据目前为80%。
  • 完整全包膜切除、全包膜切除或部分包膜切除均显示相似的症状改善,基于包膜切除术类型的症状减少无统计学差异。
  • 自我报告乳房假体疾病的患者取出假体后症状有统计学显著改善,且这种改善至少持续6个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast Implant Illness (BII) is a term used to describe a variety of symptoms by patients with breast implants for which there are no abnormal physical or laboratory findings to explain their symptoms. There currently exists a difference of opinion among clinicians and patients concerning the diagnosis and treatment of patients self-reporting BII. OBJECTIVES: The first aim of this study was to determine if there is a valid indication for "en bloc" capsulectomy in patients self-reporting BII and if the type of capsulectomy performed alters long-term symptom improvement. The second goal was to identify any clinical laboratory differences between the cohorts. This study was funded by the Aesthetic Surgery Education and Research Foundation (ASERF). METHODS: A prospective blinded study enrolled 150 consecutive subjects divided equally into 3 cohorts: (A) women with systemic symptoms they attribute to their implants who requested implant removal; (B) women with breast implants requesting removal or exchange who do not have symptoms they attribute to their implants; and (C) women undergoing cosmetic mastopexy who have never had any implanted medical device. The subject's baseline demographic data and a systemic symptoms survey, including PROMIS validated questionnaires, was obtained before surgery and at 3-6 weeks, 6 months, and 1 year. Blood was collected from all 3 cohorts and implant capsules were collected from Cohorts A and B. RESULTS: 150 patients were enrolled between 2019-2021. Follow-up at 3-6 weeks for all 3 cohorts was between 98%-100%, 78%-98% at 6-months, and 1 year data is currently at 80%. The type of capsulectomy; intact total, total, or partial all showed similar symptom improvement with no statistical difference in the reduction of symptoms based on the type of capsulectomy. CONCLUSIONS: This study addresses one of the most discussed questions by plastic surgeons, patients, their advocates, and social media. The findings show that patients who self-report BII demonstrate a statistically significant improvement in their symptoms after explantation and that this improvement persists for at least 6 months. This improvement in self-reported systemic symptoms was seen regardless of the type of capsulectomy performed.

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Glicksman C, McGuire P, Kadin M, et al. Impact of Capsulectomy Type on Post-Explantation Systemic Symptom Improvement: Findings From the ASERF Systemic Symptoms in Women-Biospecimen Analysis Study: Part 1. Aesthet Surg J. 2022. PMID: 34915566. doi:10.1093/asj/sjab417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。